^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CNA3103

    i
    Other names: CNA3103, LGR5-targeted CAR-T
    Associations

    News

    Trials
    Company:
    Bionomics, Carina Biotech
    Drug class:
    LGR5-targeted CAR-T immunotherapy
    Associations

    News

    Trials
    2years
    A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Carina Biotech Limited
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases
    |
    LGR5 (Leucine Rich Repeat Containing G Protein-Coupled Receptor 5)
    |
    CNA3103
    over2years
    A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Carina Biotech Limited | Not yet recruiting --> Recruiting | Initiation date: Jul 2023 --> Oct 2023
    Enrollment open • Trial initiation date • CAR T-Cell Therapy • Metastases
    |
    LGR5 (Leucine Rich Repeat Containing G Protein-Coupled Receptor 5)
    |
    CNA3103
    almost3years
    Development of a flow cytometry-based assay for measuring specific CAR expression on LGR5-targeting CAR-T cells (AACR 2023)
    We have developed several CARs targeting the cancer stem cell marker LGR5, one of which (CNA3103) is the lead candidate in an upcoming clinical trial in advanced metastatic colorectal cancer...This resulted in development of an assay that yielded very similar reproducibility and sensitivity to that previously observed with the indirect tEGFR surrogate assay. Overall, the findings highlight the utility of using CAR-targeting recombinant proteins for evaluating CAR expression on CAR-T cells, providing a general flow cytometry-based staining strategy that may be adapted for assessing a diverse repertoire of CARs.
    CAR T-Cell Therapy • IO biomarker
    |
    CD19 (CD19 Molecule) • LGR5 (Leucine Rich Repeat Containing G Protein-Coupled Receptor 5)
    |
    CNA3103
    almost3years
    A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=44, Not yet recruiting, Carina Biotech Pty Ltd
    New P1/2 trial • CAR T-Cell Therapy • Metastases
    |
    LGR5 (Leucine Rich Repeat Containing G Protein-Coupled Receptor 5)
    |
    CNA3103